Table 4.
Differences in chronotype, anti-psychotic medication, hours slept, hours spent in bed, and rMEQ scores for psychosis and non-psychosis groups.
| Psychosis | Non-psychosis | ||
|---|---|---|---|
| n= 43 | n= 12 | p | |
| ANOVA | |||
| Definite morning | 6 | 3 | 0.773 |
| Moderate morning | 8 | 3 | |
| Intermediate | 19 | 2 | |
| Moderate evening | 10 | 3 | |
| Definite evening | 0 | 1 | |
| t-Test | |||
| rMEQ score, M (SD) | 15.4 (4.7) | 16.0 (6.6) | 0.731 |
| MSFSC (time), M (SD) | 3:48 (1:21) | 2:56 (1:10) | 0.120 |
| Social jetlag (minutes), M (SD) | 5.7 (15.1) | 32.2 (52.4) | 0.190 |
| Bed time, M (SD) | 22:00 (1:08) | 22:42 (2:11) | 0.440 |
| Hours in bed, M (SD) | 10.1 (1.7) | 7.6 (2.4) | 0.001 |
| Hours slept, M (SD) | 8.6 (1.6) | 5.4 (2.3) | <0.001 |
| Anti-psychotic dose (CPZ equiv.), M (SD) | 736 (520) | 138 (289) | <0.001 |
rMEQ, reduced Morningness–Eveningness Questionnaire; low rMEQ scores indicate preference eveningness and high scores indicate preference for morningness; ANOVA, analysis of variance; MSFSC, Mid-sleep on free days corrected for sleep debt on work days; CPZ equiv., daily scheduled intake of anti-psychotic medication in chlorpromazine equivalents.